MPIMalaysian Pharmaceutical
Intelligence
BETASearchSign in
The fields · the register by therapeutic area

Every therapeutic field in Malaysian medicine.

Seven fields, 4,588 molecules, one register. Each field described the same way — how its market is structured by makers and patent status, and what it is worth. The facts, field by field; no verdict.

7
Fields
4,588
Molecules
2,257
NPRA products
~RM 7B
Tracked market
Generic-open — off-patent, generics registered Near cliff — expiry within 24 months Multi-source — 10+ makers Patent-protected — single maker
Metabolic & diabetes
A10 · 293 products · 87 makers
Biguanides, sulfonylureas, DPP-4, SGLT2, GLP-1, insulins. Market value sits mostly in the newer classes.
12
8
22
30
Most makers: Metformin (31) · newest off-patent: Dapagliflozin (2023)
RM 1.3–1.8B
+45% / 2yr
Open the field →
Cardiovascular
C · 261 products · 72 makers
Statins, DOACs, ARNI, antihypertensives, PCSK9. The DOAC class is the newest to go multi-source.
9
6
26
19
Most makers: Atorvastatin (28) · newest off-patent: Apixaban (2022)
RM 1.1–1.5B
+18% / 2yr
Open the field →
Oncology
L01 · 178 products · 41 makers
TKIs, monoclonal antibodies, hormonals, cytotoxics. Most value sits in patent-protected biologics.
6
9
11
40
Most makers: Imatinib (9) · protected: Trastuzumab, Pembrolizumab
RM 0.9–1.4B
+31% / 2yr
Open the field →
Immunology
L04 · 94 products · 26 makers
TNF inhibitors, interleukins, JAK inhibitors. Largely biologic; biosimilars beginning to register.
4
5
9
22
Biosimilar-registered: Adalimumab, Etanercept · protected: Ustekinumab
RM 0.7–1.1B
+52% / 2yr
Open the field →
Neurology
N · 212 products · 55 makers
Antiepileptics, antipsychotics, antidepressants, CGRP antagonists. Older classes multi-sourced; newest are specialty.
7
4
24
14
Most makers: Gabapentin (19) · protected: Erenumab (CGRP)
RM 0.6–0.9B
+12% / 2yr
Open the field →
Respiratory
R · 143 products · 45 makers
Inhaled corticosteroids, LABA/LAMA, leukotriene antagonists, biologics. Device-based products dominate.
5
5
18
17
Most makers: Montelukast (16) · protected: Dupilumab (biologic)
RM 0.5–0.8B
+9% / 2yr
Open the field →
Anti-infectives
J · 321 products · 91 makers
Antibiotics, antivirals, antifungals, vaccines. The most multi-sourced field; demand shaped by stewardship policy.
8
3
34
9
Most makers: Amoxicillin (40+) · newest off-patent: Linezolid
RM 0.8–1.1B
+7% / 2yr
Open the field →